ALLMedicine™ Factor X Center
Research & Reviews 450 results
PloS One; Traets MJM, Nijhuis RHT et. al.
Jan 8th, 2022 - Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can manifest with varying disease severity and mortality. Genetic predisposition influences the clinical course of infectious diseases...
Seminars in Thrombosis and Hemostasis; Ichinose A, Osaki T et. al.
Dec 24th, 2021 - Coagulation factor V (or FV for the purpose of medical safety) is an essential cofactor of coagulation factor X in the common pathway of coagulation; severe FV deficiency leads to a bleeding tendency. Although both congenital and acquired FV defic...
Journal of Thrombosis and Haemostasis : JTH; Bonde AC, Lund J et. al.
Dec 21st, 2021 - The regulation of factor X (FX) is critical to maintain the balance between blood coagulation and fluidity. To functionally characterize the role of the FX autolysis loop in the regulation of the zymogen and active form of FX. We introduced novel ...
https://doi.org/10.1038/s41388-021-02147-z 10.1038/s41580-019-0199-y 10.1016/j.cell.2017.04.001 10.1038/nrm.2017.95 10.1038/sj.onc.1205662 10.1073/pnas.0502857102 10.1016/j.cell.2008.06.028 10.1016/j.molcel.2010.09.026 10.1016/S1097-2765(01)00323-9 10.1016/j.cell.2008.12.002 10.1093/jmcb/mjx051 10.1158/1541-7786.MCR-15-0159 10.1126/sciadv.1603204 10.1158/0008-5472.CAN-06-4149 10.1038/s41419-020-03185-3 10.1038/s41467-017-02088-w 10.1038/onc.2013.589 10.1101/gad.340919.120 10.1016/j.jhep.2020.07.036 10.1016/S1097-2765(02)00706-2 10.1101/gad.1617608 10.1158/0008-5472.CAN-10-1769 10.1016/j.cell.2014.08.038 10.1016/j.celrep.2014.10.019 10.1038/s41388-019-0706-9 10.1016/j.trecan.2020.08.007 10.1038/s41467-019-08578-3 10.1182/blood-2018-09-871418 10.1016/j.trecan.2019.11.001 10.1038/s41590-018-0144-9 10.1093/nar/gkab575 10.1093/nar/gkw523 10.1042/BJ20070797 10.1016/j.cell.2017.03.023 10.1101/gad.264127.115 10.1042/bj3540275 10.1038/onc.2009.248 10.1093/nar/gky1094 10.1101/gr.220533.117 10.1093/nar/gkt504
Oncogene Coronel L, Häckes D et. al.
Dec 16th, 2021 - In recent years the tumor suppressor p53 has been increasingly recognized as a potent regulator of the cell metabolism and for its ability to inhibit the critical pro-survival kinases AKT and mTOR. The mechanisms through which p53 controls AKT and...
Journal of Thrombosis and Haemostasis : JTH; Paul D, Morrissey JH
Dec 12th, 2021 - Cellular trauma or activation exposes phosphatidylserine (PS) and the substantially more abundant phospholipid, phosphatidylethanolamine (PE), on the outer layer of the plasma membrane, thereby allowing binding of many blood clotting proteins. We ...
Drugs 5 results see all →
Clinicaltrials.gov 11 results
Sep 23rd, 2021 - 250 patients of similar age, gender, and ethnicity will be divided into five groups: Group A1-3: 150 patients with indications for cardiac implantable electronic device (CIED) implantation; Group B: 50 patients with an CIED implanted 8-10 years ag...
Sep 10th, 2020 - All patients will be monitored during their PICU stay. Clinical characteristics include: age, gender, co-morbidities, organ support therapies (mechanical ventilation, renal replacement therapy, extracorporeal membrane oxygenation, vasopressors), o...
Feb 5th, 2019 - To investigate the safety and efficacy of FACTOR X administered by bolus infusion to prevent bleeding and achieve haemostasis in factor X deficient subjects undergoing surgery.
Mar 29th, 2018 - Background In clinical kidney transplantation organ retrieval, cold-preservation of the graft as well as restoration of the blood flow to the transplant cause tissue damage (ischemia/reperfusion injury). Clinically these events can manifest themse...
Jan 27th, 2017 - The current standard therapy for Acute Pulmonary Embolism (APE) involves admitting patients to the hospital for administration of parenteral anticoagulation therapy(Unfractionated Heparin, Low Molecular Weight Heparin, or Fondaparinux) as a bridge...
News 26 results
Mar 18th, 2019 - HONOLULU – Andexanet alfa rapidly reverses factor Xa inhibition and effectively establishes hemostasis in patients with acute major bleeding, according to a study presented at the International Stroke Conference sponsored by the American Heart Ass.
Aug 30th, 2018 - In patients with hemophilia A who do not have factor VIII inhibitors, emicizumab therapy outperformed factor VIII prophylaxis, according to a results of a randomized, open-label, phase 3 trial. Crystal/Wikimedia Commons/Creative Commons Attributio.
Jun 7th, 2018 - By Crystal (Crystl) from Bloomington, USA - Flickr Bleeding human finger The US Food and Drug Administration (FDA) has granted priority review for emicizumab (Hemlibra®) for adults and children with hemophilia A without factor VIII inhibitors. Ear.
Apr 18th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to emicizumab (Hemlibra®) for patients who have hemophilia A without factor VIII inhibitors. Emicizumab is a bisp.
Mar 27th, 2018 - Photo from Business Wire Emicizumab (Hemlibra) Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the bispecific factor IXa- and factor X-directed antibody emicizumab (Hemlibra), according to Chugai Pharmaceutical Co. , Ltd.